An anemarrhena asphodeloides polysaccharide aap1-1-a, a preparation method and application thereof

Abstract

This invention relates to the fields of pharmaceuticals and health foods, and particularly to a polysaccharide from *Anemarrhena asphodeloides* AAP1-1-A, its preparation method, and its applications. The invention involves mixing *Anemarrhena asphodeloides* rhizome powder with water for extraction, obtaining an extract; concentrating the extract, mixing the concentrate with ethanol, and precipitating the concentrate to obtain crude polysaccharide; subjecting the crude polysaccharide to protein removal, dialysis, and freeze-drying to obtain *Anemarrhena asphodeloides* polysaccharide AA1; and then performing ion-exchange column chromatography and molecular sieve gel column chromatography on *Anemarrhena asphodeloides* polysaccharide AA1 to obtain *Anemarrhena asphodeloides* polysaccharide AAP1-1-A. The molecular weight of *Anemarrhena asphodeloides* polysaccharide AAP1-1-A is 1000~100000 Da. The preparation method is simple, the reaction conditions are mild, and it can be produced on a large scale. Furthermore, the *Anemarrhena asphodeloides* polysaccharide AAP1-1-A obtained by this invention lays the foundation for the development of *Anemarrhena asphodeloides* polysaccharide as an anti-Parkinson's disease active drug, health food, and functional food, as well as for its quality control and in-depth research on its structure-activity relationship and mechanism of action.

Description

Technical Field

[0001] This invention relates to the fields of medicine and health food technology, and in particular to a polysaccharide of Anemarrhena asphodeloides AAP1-1-A, its preparation method and application. Background Technology

[0002] The continued aging of the global population is closely related to the significant increase in the incidence of neurodegenerative diseases. Parkinson's disease, as the second most common neurodegenerative disease, places a heavy disease burden and economic pressure on global public health systems. The disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra of the midbrain and abnormal accumulation of α-synuclein. Current clinical treatment primarily relies on levodopa replacement therapy, but long-term use can easily lead to reduced efficacy, dyskinesia, and other serious side effects, and it cannot halt disease progression. Therefore, finding novel treatment strategies that can intervene at multiple targets, have neuroprotective effects, and have mild side effects has become an urgent need in the field of Parkinson's disease research.

[0003] Polysaccharides, as a class of natural biomolecules widely found in plants, animals, and microorganisms, have attracted much attention due to their structural diversity and good biocompatibility. Numerous studies have shown that natural polysaccharides possess remarkable antioxidant, anti-inflammatory, immunomodulatory, and neurotrophic activities, exerting protective effects on the nervous system through multiple pathways, including inhibiting oxidative stress, reducing neuroinflammation, regulating mitochondrial function, and inhibiting apoptosis. Therefore, plant-derived natural polysaccharides, with their advantages of multi-target targeting, low toxicity, and broad pharmacological activities, offer new research directions and hope for developing potential neuroprotective agents or adjuvant therapies for Parkinson's disease.

[0004] Anemarrhena asphodeloides ( Rhodomyrtus tomentosa Anemarrhena asphodeloides (Ait.) Hassk. is a commonly used traditional Chinese medicine in the Liliaceae family. Its dried rhizome is used medicinally, possessing the effects of clearing heat and purging fire, nourishing yin and moistening dryness. Modern pharmacological studies have revealed that extracts of Anemarrhena asphodeloides and its active components (such as anemarrhena saponins and anemarrhena polysaccharides) show significant potential in improving cognitive dysfunction, regulating glucose and lipid metabolism, anti-inflammation, and neuroprotection. However, research on polysaccharides, one of its main active components, in the prevention and treatment of Parkinson's disease is scarce. Currently, there is a lack of research on the preparation of homogeneous components of Anemarrhena asphodeloides polysaccharides, structural analysis, and their systemic pharmacological activity against key pathological links in Parkinson's disease. Therefore, it is necessary to provide a method for the extraction and purification of Anemarrhena asphodeloides polysaccharides to lay the foundation for quality control and in-depth research on their Parkinsonian activity. Summary of the Invention

[0005] The purpose of this invention is to provide anemarrhena polysaccharide AAP1-1-A, its preparation method, and its application, so as to solve the problems existing in the prior art.

[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution: One of the technical solutions of this invention provides a method for preparing Anemarrhena asphodeloides polysaccharide AAP1-1-A, comprising the following steps: 1) Mix the powdered rhizome of Anemarrhena asphodeloides with water and extract the extract to obtain the extract; 2) Concentrate the extract to obtain a concentrated solution; 3) Mix the concentrated liquid with ethanol, precipitate with alcohol, let stand, collect the precipitate, and obtain crude polysaccharide; 4) The crude polysaccharide was subjected to protein removal, dialysis, and freeze-drying in sequence to obtain Anemarrhena asphodeloides polysaccharide AA1; 5) Anemarrhena polysaccharide AA1 was subjected to ion exchange column chromatography with gradient elution using 0-2M sodium chloride solution. The elution curve was tracked using the phenol-sulfuric acid method. The eluted fraction of 0M sodium chloride solution was collected according to the elution curve, concentrated, and freeze-dried to obtain Anemarrhena polysaccharide AAP1. 6) Dissolve Anemarrhena polysaccharide AAP1 in water, centrifuge, take the supernatant, perform molecular sieve gel column chromatography on the supernatant, elute with water, detect the elution curve using the phenol-sulfuric acid method, collect the sugar fraction according to the elution curve, concentrate and freeze dry to obtain Anemarrhena polysaccharide AAP1-1-A.

[0007] The second technical solution of the present invention provides a polysaccharide AAP1-1-A prepared by the above preparation method, wherein the molecular weight of the polysaccharide AAP1-1-A is 1000~100000 Da; and the polysaccharide AAP1-1-A is a homogeneous polysaccharide.

[0008] The third technical solution of the present invention provides an application of the above-mentioned Anemarrhena asphodeloides polysaccharide AAP1-1-A in the preparation of anti-Parkinson's drugs or health products.

[0009] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention uses water extraction and alcohol precipitation to preliminarily separate Anemarrhena asphodeloides polysaccharides, with significant results. Moreover, this preparation method is simple, the reaction conditions are mild, and it can be produced on a large scale.

[0010] 2. This invention uses column chromatography to perform secondary separation and purification of Anemarrhena asphodeloides polysaccharide, with significant results, and for the first time prepares a pure Anemarrhena asphodeloides polysaccharide AAP1-1-A.

[0011] 3. The present invention identified the structure of the purified Anemarrhena asphodeloides polysaccharide AAP1-1-A, clarified the physicochemical properties of each polysaccharide component, and provided structural basis for exploring its pharmacological activity mechanism.

[0012] 4. The pure Anemarrhena asphodeloides polysaccharide AAP1-1-A obtained by this invention has well-preserved components and controllable quality. It can restore the motor ability and motor neurons of Parkinson's zebrafish to exert anti-Parkinson's activity, providing a basis for the application of Anemarrhena asphodeloides polysaccharide in the fields of medicine and health products.

[0013] 5. This invention lays the foundation for the development of Anemarrhena asphodeloides polysaccharide drugs, quality control, and in-depth research on its structure-activity relationship and mechanism of action. Attached Figure Description

[0014] Figure 1 The high-performance liquid chromatogram of Anemarrhena asphodeloides polysaccharide AAP1-1-A; Figure 2 Infrared spectrum of Anemarrhena asphodeloides polysaccharide AAP1-1-A; Figure 3 The effects of Anemarrhena asphodeloides polysaccharide AAP1-1-A on the behavior of Pakin zebrafish were investigated. (a) shows the swimming trajectory of zebrafish in different groups; (b) shows the percentage of time spent moving at different speeds; (c) shows the total distance moved by zebrafish; and (d) shows the average speed of zebrafish. Figure 4 The effects of Anemarrhena asphodeloides polysaccharide AAP1-1-A on motor neurons in zebrafish with Parkinson's disease are shown in (a) and (b) respectively. (a) is a fluorescence image of zebrafish motor neurons and (b) is a quantitative statistical graph of the fluorescence signal intensity of zebrafish motor neurons. Detailed Implementation

[0015] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0016] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0017] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0018] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be obvious to those skilled in the art. This application specification and embodiments are merely exemplary.

[0019] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0020] The room temperature described in this invention is 25±2℃.

[0021] All raw materials used in this invention can be obtained commercially or prepared using existing technologies.

[0022] This invention provides a method for preparing Anemarrhena asphodeloides polysaccharide AAP1-1-A, which has a significant effect against Parkinson's disease. The method includes the following steps: 1) Mix the powdered rhizome of Anemarrhena asphodeloides with water and extract the extract to obtain the extract; 2) Concentrate the extract to obtain a concentrated solution; 3) Mix the concentrated liquid with ethanol, precipitate with alcohol, let stand, collect the precipitate, and obtain crude polysaccharide; 4) The crude polysaccharide was subjected to protein removal, dialysis, and freeze-drying in sequence to obtain Anemarrhena asphodeloides polysaccharide AA1; 5) Anemarrhena polysaccharide AA1 was subjected to ion exchange column chromatography with gradient elution using 0-2M sodium chloride solution. The elution curve was tracked using the phenol-sulfuric acid method. The eluted fraction of 0M sodium chloride solution was collected according to the elution curve, concentrated, and freeze-dried to obtain Anemarrhena polysaccharide AAP1. 6) Dissolve Anemarrhena polysaccharide AAP1 in water, centrifuge, take the supernatant, perform molecular sieve gel column chromatography on the supernatant, elute with water, detect the elution curve using the phenol-sulfuric acid method, collect the sugar fraction according to the elution curve, concentrate and freeze dry to obtain Anemarrhena polysaccharide AAP1-1-A.

[0023] This invention combines water extraction with alcohol precipitation. High-concentration ethanol can separate highly polar and water-soluble polysaccharides from less polar and poorly water-soluble polysaccharides, solving the problem of complicated and difficult separation in the later stages caused by traditional water boiling method for polysaccharide extraction.

[0024] Step 1) of this invention involves crushing the dried rhizome of Anemarrhena asphodeloides, washing it with water, and drying it to obtain rhizome powder; adding water to the rhizome powder for extraction, filtering, and obtaining the extract.

[0025] In this invention, the mass of water in step 1) is 6 to 10 times the mass of the Anemarrhena asphodeloides rhizome powder, for example, it can be 6, 7, 8, 9 or 10 times, etc.

[0026] In this invention, the extraction temperature is 60~80℃, for example, 60℃, 70℃ or 80℃, the time is 1~3h, for example, 1h, 2h or 3h, and the number of extractions is 2~4.

[0027] Step (2) of this invention is to concentrate the extract under reduced pressure to obtain a concentrated solution; In this invention, the concentration temperature is 40~70℃, for example, it can be 40℃, 50℃, 60℃ or 70℃, the vacuum degree is -0.1MPa, and the time is 1~3 h, for example, it can be 1 h, 2 h or 3 h.

[0028] Step 3 of this invention is to add ethanol to concentrate 1, with the volume of ethanol being a%, let it stand, collect the precipitate and supernatant, and obtain crude polysaccharide AA1 and supernatant 1. In this invention, step 3) involves adding ethanol to the concentrate until the ethanol volume concentration is 50%; the standing time is 10-15 hours, for example, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours or 15 hours.

[0029] The present invention also provides an anemarrhena polysaccharide AAP1-1-A prepared by the above preparation method, which has a significant anti-Parkinson's disease effect. The molecular weight of the anemarrhena polysaccharide AAP1-1-A is 1000~100000 Da. The anemarrhena polysaccharide AAP1-1-A is a homogeneous polysaccharide.

[0030] This invention uses dried Anemarrhena asphodeloides powder as raw material, and separates crude polysaccharides by water extraction and alcohol precipitation. The extracted crude polysaccharides are then deproteinized, and purified by ion exchange chromatography and gel molecular sieve column chromatography. For the first time, a pure Anemarrhena asphodeloides polysaccharide was prepared. The physicochemical properties, molecular weight, and infrared spectrum of this pure polysaccharide were systematically analyzed and identified, and the basic characterization information of Anemarrhena asphodeloides polysaccharide was successfully obtained. Among them, Anemarrhena asphodeloides polysaccharide AAP1-1-A is a homogeneous polysaccharide.

[0031] This invention also provides the application of the above-mentioned Anemarrhena asphodeloides polysaccharide AAP1-1-A in the preparation of anti-Parkinson's drugs or health products.

[0032] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0033] Example 1 A method for preparing Anemarrhena asphodeloides polysaccharide AAP1-1-A includes the following steps: S1, Crushing 1 kg of dried rhizome of Anemarrhena asphodeloides was crushed, quickly washed with cold water, and dried to obtain rhizome powder. S2, water extraction Add water at 8 times its weight to the mother rhizome powder obtained in step S1, heat to 70°C and extract, extract for 1 hour each time, for a total of 3 extractions, collect the extract, dry the residue, and obtain the extract and residue. S3, graded alcohol precipitation The extract obtained in step S2 was concentrated at 60℃ under reduced pressure (vacuum degree -0.1MPa) for 1h to obtain concentrate 1; ethanol was added to concentrate 1 until the ethanol volume concentration was 50%, and the mixture was allowed to stand for 15h. The precipitate and supernatant were collected to obtain crude polysaccharide AA1 and supernatant 1. S4, Purification S4-01, First Purification The crude polysaccharide AA1 obtained in step S3 was deproteinized using the Sevag method. After deproteinization, the crude polysaccharide was dialyzed and lyophilized using a dialysis bag (with a molecular weight cutoff of 3500 Da) to obtain the mother polysaccharide AA1. S4-02, Secondary Purification 800 mg of Anemarrhena asphodeloides polysaccharide AA1 was dissolved in 10 mL of deionized water and loaded onto a DEAE-FF column. Gradient elution was performed using 0–2 M NaCl solution, resulting in one elution peak. The elution peak was the 0 M NaCl elution fraction (the elution curve was tracked using the phenol-sulfuric acid method during elution, and the sugar fractions were collected according to the elution curves). The obtained eluents were concentrated and freeze-dried to obtain Anemarrhena asphodeloides polysaccharide AAP1. The above-mentioned freeze-dried Anemarrhena asphodeloides polysaccharide AAP1 was dissolved in water, centrifuged, and the supernatant was loaded onto a Sephadex G-100 column and eluted with 0 M NaCl. The elution curve was tracked using the phenol-sulfuric acid method, and a single symmetrical peak appeared. The main peak was collected, concentrated, and freeze-dried to obtain Anemarrhena asphodeloides polysaccharide AAP1-1-A.

[0034] Example 2 Structural analysis of Anemarrhena asphodeloides polysaccharide AAP1-1-A (a) Experimental material: Anemarrhena polysaccharide AAP1-1-A from Example 1.

[0035] (II) Test Methods: 1. Homogeneity and molecular weight analysis Sample processing: Accurately weigh 5 mg of Anemarrhena asphodeloides polysaccharide AAP1-1-A and dissolve it in 1 mL of deionized water. Filter the solution through a 0.22 μm filter membrane before HPLC analysis.

[0036] Chromatographic column: TSKgel G3000PWXL, 7.8 × 300 mm, 7 μm; mobile phase: 0.02 M phosphate buffer; detector: RID; flow rate: 0.5 mL / min; injection volume: 10 μL.

[0037] 2. Infrared spectroscopy detection 2.0 mg of dried Anemarrhena asphodeloides polysaccharide AAP1-1-A was ground with KBr, compressed into tablets, and tested using IR Affinity-1 at 4000-4000 cm⁻¹. -1 Scan within the range.

[0038] (III) Test Results: 1. Structural characterization of Anemarrhena asphodeloides polysaccharide AAP1-1-A (1) Homogeneity analysis like Figure 1 As shown in the HPLC chromatogram, the polysaccharide AAP1-1-A of Anemarrhena asphodeloides exhibits a single symmetrical peak, indicating that AAP1-1-A is a homogeneous polysaccharide with a molecular weight range of 1000~100000 Da.

[0039] (2) Infrared spectroscopy analysis like Figure 2 As shown in the infrared spectrum of Anemarrhena asphodeloides polysaccharide AAP1-1-A, it can be seen that Anemarrhena asphodeloides AAP1-1-A contains the characteristic infrared absorption peaks of polysaccharides.

[0040] Example 3 Study on the anti-Parkinson's effect of pure Anemarrhena asphodeloides polysaccharide AAP1-1-A on zebrafish (a) Experimental material: Anemarrhena polysaccharide AAP1-1-A from Example 1.

[0041] (ii) Experimental subject: Zebrafish (purchased from Nanjing Yishu Lihua Technology Co., Ltd.).

[0042] (III) Test Methods: 1. Zebrafish culture: Adult zebrafish were reared in an automated system at 28 ± 0.5 ℃ with alternating light and dark cycles of 14 h and 10 h. Spawning was induced and eggs were collected, then transferred to E3 medium (0.33 mmol / L CaCl2, 5.00 mmol / L NaCl, 0.18 mmol / L KCl, 0.34 mmol / L MgSO4, pH 7.40) and placed in an incubator at 28.5 ℃.

[0043] 2. Administration Fertilized AB zebrafish larvae at 2 dpf and Tg(HuC:GFP) zebrafish larvae were randomly transferred to each well of a 24-well plate, with 20 larvae placed in each well. A blank control group, a model group, a positive control group, and different concentrations of polysaccharide-treated groups were established, with 3 wells in each group. The fish were cultured in a 28.5 ℃ incubator until 5 dpf (14 h light / 10 h dark).

[0044] Control group: Add 2 mL of E3 culture medium Model group: 2 mL of 250 μg / mL 6-hydroxydopamine (6-OHDA) solution was added. Polysaccharide group: 2 mL of 6-OHDA at a final concentration of 250 μg / mL and polysaccharide solutions of different concentrations (100, 200, and 400 μg / mL) were added. 3. Ethical Evaluation of Zebrafish After the 5dpf experiment, the drugs were washed off, and the zebrafish were placed in 96-well plates, one per well. They were then placed in the Zebrabox zebrafish behavior analyzer and allowed to acclimatize for 10 minutes. The analysis then began, lasting 20 minutes. Data processing was performed using Zeblab software to calculate the total swimming distance and average speed of each fish.

[0045] 4. Development of neurons in zebrafish After the 5dpf experiment, the drugs were washed off, and the development of zebrafish neurons with labeled neurons was observed using a fluorescence microscope. Stereoscopic fluorescence microscope images were taken, and ImageJ was used for quantification.

[0046] (iv) Experimental Results like Figure 3-4 As shown, Anemarrhena asphodeloides polysaccharide AAP1-1-A can restore the motor function and neuronal development of Parkinson's disease zebrafish, thus exerting anti-Parkinson's disease activity. Figure 3The effects of Anemarrhena asphodeloides polysaccharide AAP1-1-A on the behavior of Parkinson's disease zebrafish were investigated. (a) shows the swimming trajectory diagrams of zebrafish in different groups. The trajectory of the blank group was dense and covered a large area, indicating that the zebrafish were active. The trajectory of the 6-OHDA model group was sparse, short and messy, reflecting the bradykinesia and stereotyped behavior of the Parkinson's disease model. In the AAP1-1-A intervention group, the trajectory gradually became denser and the range expanded with the increase of dose, indicating that the motor ability was improved. (b) is a graph showing the proportion of time spent moving at different speeds in zebrafish. As the concentration of AAP1-1-A increases, the proportion of time spent moving slowly gradually decreases, while the proportion of time spent moving quickly increases. At high concentrations, it approaches the level of the normal control group, indicating that AAP1-1-A can effectively restore the movement speed and vitality of animals. (c) is a graph showing the total movement distance of zebrafish. The total distance in the model group is significantly shortened, while after AAP1-1-A treatment, the total distance increases with increasing dose, proving that polysaccharides can improve bradykinesia. (d) is a graph showing the average movement speed of zebrafish. The speed in the model group is significantly reduced, while the speed recovers after AAP1-1-A intervention, approaching the normal level at 400 μg / mL, further verifying its effect on improving motor function.

[0047] Figure 4 The study investigated the effects of Anemarrhena asphodeloides polysaccharide AAP1-1-A on motor neurons in zebrafish with Parkinson's disease. (a) showed that the fluorescence intensity of zebrafish motor neurons gradually increased and the fluorescence signal gradually recovered with increasing polysaccharide dosage, indicating that the neuronal damage was significantly improved. (b) was a quantitative statistical graph of the fluorescence signal intensity, which quantitatively demonstrated that the protective effect of AAP1-1-A on neurons was dose-dependent.

[0048] In summary, the pure polysaccharide AAP1-1-A prepared by this invention is a homogeneous polysaccharide, and it can restore the motor ability and neuronal development of Parkinson's disease zebrafish to exert anti-Parkinson's disease activity.

[0049] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A method for preparing Anemarrhena asphodeloides polysaccharide AAP1-1-A, characterized in that, Includes the following steps: 1) Mix the powdered rhizome of Anemarrhena asphodeloides with water and extract the extract to obtain the extract; 2) Concentrate the extract to obtain a concentrated solution; 3) Mix the concentrated liquid with ethanol, precipitate with alcohol, let stand, collect the precipitate, and obtain crude polysaccharide; 4) The crude polysaccharide was subjected to protein removal, dialysis, and freeze-drying in sequence to obtain Anemarrhena asphodeloides polysaccharide AA1; 5) Anemarrhena polysaccharide AA1 was subjected to ion exchange column chromatography with gradient elution using 0-2M sodium chloride solution. The elution curve was tracked using the phenol-sulfuric acid method. The eluted fraction of 0M sodium chloride solution was collected according to the elution curve, concentrated, and freeze-dried to obtain Anemarrhena polysaccharide AAP1. 6) Dissolve Anemarrhena polysaccharide AAP1 in water, centrifuge, take the supernatant, perform molecular sieve gel column chromatography on the supernatant, elute with water, detect the elution curve using the phenol-sulfuric acid method, collect the sugar fraction according to the elution curve, concentrate and freeze dry to obtain Anemarrhena polysaccharide AAP1-1-A.

2. The preparation method according to claim 1, characterized in that, In step 1), the mass of water should be 6 to 10 times the mass of the Anemarrhena asphodeloides root and rhizome powder.

3. The preparation method according to claim 1, characterized in that, The extraction temperature is 60~80℃, the time is 1~3h, and the number of extractions is 2~4.

4. The preparation method according to claim 1, characterized in that, The concentration is carried out at a temperature of 40~70℃, a vacuum degree of -0.1MPa, and a time of 1~3h.

5. The preparation method according to claim 1, characterized in that, Step 3) involves adding ethanol to the concentrate until the ethanol volume concentration reaches 50%; the settling time is 10-15 hours.

6. An Anemarrhena asphodeloides polysaccharide AAP1-1-A prepared by the preparation method according to any one of claims 1 to 5, characterized in that, The molecular weight of the Anemarrhena asphodeloides polysaccharide AAP1-1-A is 1000~100000 Da; the Anemarrhena asphodeloides polysaccharide AAP1-1-A is a homogeneous polysaccharide.

7. The use of Anemarrhena asphodeloides polysaccharide AAP1-1-A as described in claim 6 in the preparation of anti-Parkinson's drugs or health products.

Images